DK1635875T3 - In-situ-geldannende lægemiddeladministrationssystem - Google Patents

In-situ-geldannende lægemiddeladministrationssystem

Info

Publication number
DK1635875T3
DK1635875T3 DK04756068T DK04756068T DK1635875T3 DK 1635875 T3 DK1635875 T3 DK 1635875T3 DK 04756068 T DK04756068 T DK 04756068T DK 04756068 T DK04756068 T DK 04756068T DK 1635875 T3 DK1635875 T3 DK 1635875T3
Authority
DK
Denmark
Prior art keywords
drug administration
administration system
situ gelling
gelling drug
situ
Prior art date
Application number
DK04756068T
Other languages
Danish (da)
English (en)
Inventor
Paul Ashton
Jianbing Chen
Dongling Su
Original Assignee
Psivida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida Inc filed Critical Psivida Inc
Application granted granted Critical
Publication of DK1635875T3 publication Critical patent/DK1635875T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04756068T 2003-06-26 2004-06-25 In-situ-geldannende lægemiddeladministrationssystem DK1635875T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48267703P 2003-06-26 2003-06-26
US57530704P 2004-05-28 2004-05-28
PCT/US2004/020369 WO2005002625A2 (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system

Publications (1)

Publication Number Publication Date
DK1635875T3 true DK1635875T3 (da) 2009-01-12

Family

ID=33567657

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04756068T DK1635875T3 (da) 2003-06-26 2004-06-25 In-situ-geldannende lægemiddeladministrationssystem

Country Status (16)

Country Link
US (4) US20050048123A1 (de)
EP (2) EP1635875B8 (de)
JP (1) JP5229768B2 (de)
CN (2) CN1863557B (de)
AR (1) AR044926A1 (de)
AT (1) ATE410186T1 (de)
CA (1) CA2530136C (de)
CY (1) CY1108685T1 (de)
DE (1) DE602004016995D1 (de)
DK (1) DK1635875T3 (de)
ES (1) ES2315680T3 (de)
PL (1) PL1635875T3 (de)
PT (1) PT1635875E (de)
SI (1) SI1635875T1 (de)
TW (1) TWI377958B (de)
WO (1) WO2005002625A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
JP4827626B2 (ja) * 2006-06-14 2011-11-30 キヤノン株式会社 被制御機器、遠隔制御システムおよび遠隔制御システムの制御方法、プログラム
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
US20110059921A1 (en) * 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
JP2011513337A (ja) * 2008-04-18 2011-04-28 ウォーソー・オーソペディック・インコーポレーテッド 椎間板ヘルニアを治療するための方法および組成物
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB201014591D0 (en) * 2010-09-02 2010-10-13 Univ Nottingham Compositions
MX347014B (es) * 2010-11-24 2017-04-07 Durect Corp Composición para administración de fármaco biodegradable.
CN103717206A (zh) * 2011-07-27 2014-04-09 波利皮得有限公司 用于肽分子和多肽分子的受控释放的基质组合物
EP2956096A1 (de) * 2013-02-15 2015-12-23 Allergan, Inc. Implantat mit langzeit-wirkstofffreisetzung
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2965895C (en) 2014-11-07 2019-08-06 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
EP4445952A2 (de) 2014-12-15 2024-10-16 The Johns Hopkins University Sunitinibformulierungen und verfahren zur verwendung davon bei der behandlung von glaukom
EP3352735B1 (de) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Olanzapinformulierungen mit verzögerter freisetzung
TWI641387B (zh) * 2015-10-29 2018-11-21 逸達生物科技股份有限公司 安定性經改善之醫藥組成物
AU2016353355B9 (en) 2015-11-12 2022-09-29 Graybug Vision, Inc. Aggregating microparticles for therapy
AU2018235712A1 (en) * 2017-03-14 2019-10-03 The Children's Hospital Of Philadelphia Cleavable esters for nanocarrier-based cancer therapy
AU2018238136A1 (en) 2017-03-20 2019-11-07 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
RU2019133337A (ru) 2017-03-23 2021-04-23 Грейбуг Вижн, Инк. Лекарственные средства и композиции для лечения глазных нарушений
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
WO2018227187A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
WO2018227293A1 (en) * 2017-06-13 2018-12-20 The University Of British Columbia Polymeric paste compositions for drug delivery
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
US20220040201A1 (en) * 2018-09-25 2022-02-10 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
WO2020190606A1 (en) * 2019-03-15 2020-09-24 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
CN111374940A (zh) * 2020-04-13 2020-07-07 宁波赛缪斯生物科技有限公司 一种可原位聚合的胶原注射剂及其使用方法
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
JP2024529009A (ja) 2021-07-06 2024-08-01 マーク・ヘースルトン セロトニン再取り込み阻害剤離脱症候群の治療

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
JPS59110607A (ja) 1982-12-17 1984-06-26 シ−トン・カンパニ− 医薬化粧品用軟質連続フイルム
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
EP0406315B1 (de) 1988-03-24 1992-11-11 Bukh Meditec A/S Geregelte verabreichungszusammensetzung
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5681964A (en) 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
ES2171186T3 (es) * 1994-04-08 2002-09-01 Atrix Lab Inc Composiciones liquidas de difusion.
GB9409281D0 (en) 1994-05-10 1994-06-29 Svedman Paul Transdermal device
US5607686A (en) 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
ES2158611T3 (es) 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6102887A (en) * 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use
ES2213404T3 (es) 1998-12-17 2004-08-16 Alza Corporation Transformacion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples revestimientos.
HUP0201626A3 (en) 1999-06-04 2004-05-28 Alza Corp Mountain View Implantable gel compositions and method of manufacture
KR100416242B1 (ko) * 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
CN1283215C (zh) * 2000-06-28 2006-11-08 A·J·舒克拉 生物活性物质的可生物降解载体和释放系统
CN1206001C (zh) * 2000-06-28 2005-06-15 A·J·舒克拉 生物可降解载体和生物可降解传输系统
ATE537845T1 (de) * 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20030039689A1 (en) 2001-04-26 2003-02-27 Jianbing Chen Polymer-based, sustained release drug delivery system
US20060078618A1 (en) 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
EP3669887A1 (de) 2002-01-18 2020-06-24 Biogen MA Inc. Polyalkylen-polymer-verbindungen und verwendungen davon
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
JP5305135B2 (ja) 2008-08-05 2013-10-02 株式会社リコー 潤滑剤薄膜化装置、並びに、これを備える画像形成装置及びプロセスカートリッジ

Also Published As

Publication number Publication date
TW200514581A (en) 2005-05-01
EP1635875A2 (de) 2006-03-22
US20050048123A1 (en) 2005-03-03
CA2530136A1 (en) 2005-01-13
EP2044959A1 (de) 2009-04-08
ATE410186T1 (de) 2008-10-15
EP1635875B8 (de) 2008-12-24
CY1108685T1 (el) 2014-04-09
CN1863557A (zh) 2006-11-15
JP5229768B2 (ja) 2013-07-03
PL1635875T3 (pl) 2009-03-31
CA2530136C (en) 2012-10-16
AR044926A1 (es) 2005-10-12
US9566336B2 (en) 2017-02-14
PT1635875E (pt) 2008-12-09
ES2315680T3 (es) 2009-04-01
SI1635875T1 (sl) 2009-04-30
CN101862455A (zh) 2010-10-20
US20130101656A1 (en) 2013-04-25
DE602004016995D1 (de) 2008-11-20
JP2007524628A (ja) 2007-08-30
US20110165242A1 (en) 2011-07-07
CN1863557B (zh) 2010-06-16
TWI377958B (en) 2012-12-01
EP1635875B1 (de) 2008-10-08
WO2005002625A3 (en) 2005-04-21
WO2005002625A2 (en) 2005-01-13
US20140336278A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
DK1635875T3 (da) In-situ-geldannende lægemiddeladministrationssystem
DK1545662T3 (da) Lægemiddelindgivelsessystem
DK1599186T3 (da) System til administration af transmukalt lægemiddel
NO20041315L (no) Medikamentavleveringssystem
DE602004017700D1 (de) Transmukosen verabreichung
SI1631255T1 (sl) Sistem za razdeljevanje zdravil
DK1615615T3 (da) Manipulationssikre produkter til opioid tilførsel
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
NO20053224D0 (no) Patient controlled drug administration device.
DK1545467T3 (da) Faste farmaceutiske formuleringer omfattende telmisartan
NO20054534D0 (no) Leveringssystem for legemiddel og celleterapi
ATE405630T1 (de) Wirkstoffabgabesysteme
DK2609947T3 (da) Plasterlignende infusionsapparat
NO20053150D0 (no) System for administrasjon av medisin.
PT1501534E (pt) Formulacoes farmaceuticas
IL174396A0 (en) Oral drug delivery system
ATE536861T1 (de) Bioerodierbare arzneimittelabgabesysteme mit verzögerter freisetzung
AT10109U3 (de) Fentanyl-hältiges, transdermales, therapeutisches system
EP1667619A4 (de) Pharmazeutisches zufuhrsystem
ATE345776T1 (de) Osmotisches verabreichungssystem
DE60321572D1 (de) Transdermales arzneimittelverabreichungssystem
NO20043576L (no) Pharmaceutical formulation comprising melatonin
ATE546141T1 (de) Pharmazeutisches injektionspräparat
ITMI20020921A1 (it) Dispositivo per la sommistrazione di farmaci
DE10393889D2 (de) Medikament-Dosimeter-Kombipackung